

Supplemental Information

An Access to Highly Enantioenriched *cis*-3,5-Disubstituted γ -Lactones
from α -Bromoacetate and Silyl Enol Ether



Contents

I. NMR Spectra for **2a-b**, **3**, **4a-k**, **5**, **6**, **7**, **8** and **9**




II. Chiral stationary phase HPLC chromatograms of **3**, **4a-k**, **5**, **6**, **7**, **8** and **9**

N-Benzoyl-O-(2,4-diphenyl-4-oxobutanoyl)-L-threonine Isopropyl Ester (2a)

7.950
7.932
7.929
7.842
7.825
7.821
7.583
7.565
7.549
7.546
7.543
7.539
7.536
7.533
7.522
7.517
7.513
7.502
7.499
7.496
7.464
7.444
7.440
7.423
7.420
7.406
7.402
7.393
7.382
7.343
7.332
7.310
7.301
7.291
7.287
7.280
7.072
7.051
5.494
5.486
5.478
5.470
5.127
5.111
5.095
4.862
4.854
4.839
4.832
4.286
4.276
4.259
4.249
3.945
3.918
3.899
3.873
3.315
3.305
3.270
3.260
1.251
1.235
1.218
1.197
1.182








9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm








180 160 140 120 100 80 60 40 20 ppm

N-Benzoyl-*O*-(4-Methyl-4-oxo-2-phenylbutanoyl)-*L*-threonine Isopropyl Ester (**2b**)





Ethyl 4-oxo-2,4-diphenylbutanoate (3)






7.994, 7.976, 7.973, 7.594, 7.591, 7.575, 7.557, 7.554, 7.482, 7.479, 7.462, 7.444, 7.416, 7.407, 7.369, 7.357, 7.320, 7.316, 7.313, 7.309, 7.299, 7.267, 7.263, 4.292, 4.289, 4.282, 4.266, 4.263, 4.256, 4.253, 4.234, 4.231, 4.216, 4.213, 4.207, 4.204, 4.189, 4.186, 4.131, 4.128, 4.113, 4.110, 4.104, 4.100, 4.086, 4.083, 3.997, 3.994, 3.971, 3.967, 3.952, 3.949, 3.926, 3.922, 3.299, 3.296, 3.289, 3.286, 3.254, 3.250, 3.244, 1.240, 1.236, 1.222, 1.218, 1.204





cis-3,5-Diphenyldihydrofuran-2(3*H*)-one (*cis*-4a)





trans-3,5-Diphenyldihydrofuran-2(3*H*)-one (*trans*-4a)





cis-5-(4-Methoxyphenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-**4b**)






cis-5-(4-Methoxyphenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-**4c**)





cis-5-(2-Naphthyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-4d)





cis-5-(4-Methylphenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-**4e**)






cis-5-(4-Bromophenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-4f)









cis-5-(4-Chlorophenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-4g)




cis-5-(3-Bromophenyl)-3-phenyldihydrofuran-2(3*H*)-one (*cis*-**4h**)





cis-5-Methyl-3-phenyldihydrofuran-2(3*H*)-one (*cis*-**4i**)





cis-3-(4-Bromophenyl)-5-phenyldihydrofuran-2(3*H*)-one (*cis*-4j)




cis-3-(4-Chlorophenyl)-5-phenyldihydrofuran-2(3*H*)-one (*cis*-**4k**)






cis-2,4-Diphenyltetrahydrofuran (*cis*-5)





cis-2-(2-Naphthyl)-4-phenyltetrahydrofuran (*cis*-**6**)






trans-2-(2-Naphthyl)-4-phenyltetrahydrofuran (*trans*-**6**)




cis-2-(4-Methylphenyl)-4-phenyltetrahydrofuran (*cis*-7)




trans-2-(4-Methylphenyl)-4-phenyltetrahydrofuran (*trans*-7)



cis-2-(4-Chlorophenyl)-4-phenyltetrahydrofuran (*cis*-**8**)




trans-4-(4-Chlorophenyl)-2-phenyltetrahydrofuran (*trans*-**9**)




3: Chiralcel OD, 2% IPA/HXN, 0.5 ml/min




cis-4a: Chiralcel OB-H, 40% IPA/HXN, 0.5 ml/min




trans-4a: Chiralcel OD, 20% IPA/HXN, 0.5 ml/min




cis-4b: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4c: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4d: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4e: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4f: Chiralcel OJ-H, 20% IPA/HXN, 1.0 ml/min




cis-4g: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4h: Chiralcel OB-H, 40% IPA/HXN, 1.0 ml/min




cis-4i: Chiralcel OB-H, 40% IPA/HXN, 0.5 ml/min




cis-4j: Chiralcel OJ-H, 40% IPA/HXN, 0.5ml/min




cis-4k: Chiralcel OJ-H, 40% IPA/HXN, 0.5ml/min




cis-5: Chiralcel OB-H, 5% IPA/HXN, 0.5ml/min




trans-5: Chiralcel OD, 2% IPA/HXN, 0.5ml/min




cis-6: Chiralcel OJ-H, 10% IPA/HXN, 0.5ml/min




trans-6: Chiralcel OJ-H, 10% IPA/HXN, 0.5ml/min




cis-7: Chiralcel OB-H, 10% IPA/HXN, 0.5ml/min



trans-7: Chiralcel OB-H, 10% IPA/HXN, 0.5ml/min



cis-8: Chiralcel OD, 2% IPA/HXN, 0.5ml/min



trans-9: Chiralcel OD, 2% IPA/HXN, 0.5ml/min

